#### 5. 510(k) Summary Statement

FEB 2 2 2007

Submitter:

American Medical Systems (AMS)

10070 Bren Road West Minnetonka, MN 55343 Phone: 952.933.6139 FAX: 952.930.5785

**Contact Person:** 

**Brad Onstad** 

Device Common Name:

Sub-Urethral Sling System; Surgical Mesh

**Device Trade Name:** 

AMS Smart Sling System

Device Classification Name: Surgical Mesh, polymeric (OTN)

**Predicate Devices:** 

Caldera "T" Sling (K050516), Monarc Subfascial Hammock (K023516),

Sparc<sup>™</sup> Sling System (K011251)

#### **Device Description**

The AMS Smart Sling System consists of a sling and a surgical instrument (called a "Needle Passer" or Surgical Needle Instrument") for sub-urethral sling placement. The slings are made from polymeric mesh.

## **Indications for Use**

The Smart Sling System is intended for the placement of a pubourethral sling for the treatment of female stress urinary incontinence (SUI) resulting from urethral hypermobility and/or intrinsic sphincter deficiency.

## **Comparison to Predicate Devices**

The AMS Smart Sling System provides physicians an alternative surgical approach to implant sub-urethral slings to treat female stress urinary incontinence. The AMS Smart Sling System material, design and characteristics are substantially equivalent to those exhibited by T-Sling, Monarc, Sparc and other surgical meshes cleared for commercial distribution. The materials, design and characteristics of the AMS Smart Sling Surgical Needle Instrument (also called "Needle" and "Needle Passer") used for sling placement are substantially equivalent to those embodied in the Caldera "T" Sling, Monarc Subfascial Hammock Needle Passer and Sparc Sling needles as well as other surgical instruments cleared for commercial distribution.

#### Supporting Information

Substantial equivalency was supported by previously cleared and new bench and biocompatibility testing, cadaver studies and a literature review.

## **DEPARTMENT OF HEALTH & HUMAN SERVICES**





Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

Mr. Brad Onstad Regulatory Affairs Specialist American Medical Systems 10700 Bren Road West MINNETONKA MN 55343

SEP 28 2012

Re: K063713

Trade/Device Name: AMS Smart Sling System

Regulation Number: 21 CFR 878.3300 Regulation Name: Surgical mesh

Regulatory Class: II Product Code: OTN

Dated: December 14, 2006 Received: December 14, 2006

Dear Mr. Onstad:

This letter corrects our substantially equivalent letter of February 22, 2007.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Benjamin R. Fisher, Ph.D.

Directo

Division of Reproductive, Gastro-Renal, and Urological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

# **Indications for Use**

510(k) Number (if known):

Device Name: AMS Smart Sling System

Indications For Use: The Smart Sling System is intended for the placement of a

pubourethral sling for the treatment of female stress urinary incontinence (SUI) resulting from urethral hypermobility and/or

intrinsic sphincter deficiency.

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use \_\_\_\_\_(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE NEEDED)

(Division Sign-Off)

Division of General, Pestorative,

and Neurological Desces

510(k) Number K 66 37/3